Ozempic Gastroparesis Attorney: Lawsuit Eligibility Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

Legacy of Health Science Documentation

For decades, the Immunodeficiency Foundation has served as a trusted editorial archive, preserving the scientific and historical records that illuminate the complexities of human health. Our mission has always been to provide a neutral, academic foundation for understanding how biological systems function and how various factors can influence their balance. This legacy of careful documentation and public education has allowed us to explore a wide range of health-related topics, from fundamental immune mechanisms to broader public health considerations. As our understanding of health science evolves, so too does the scope of inquiry. Increasingly, the public health landscape is shaped by the widespread use of pharmaceutical interventions designed to manage chronic conditions. One such area of growing attention involves medications originally developed for metabolic regulation, which have seen expanded use across diverse patient populations. This shift in therapeutic application has prompted new questions about long-term exposure and potential unintended effects on normal physiological processes. In particular, the relationship between certain widely prescribed treatments and gastrointestinal function has become a subject of careful review.

Bridging to Ozempic and Gastroparesis

This transition from general health science to a more focused pharmaceutical exposure concern reflects the Foundation’s ongoing commitment to documenting emerging areas of scientific and legal interest, always maintaining our rigorous, evidence-informed perspective. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Its mechanism of action includes slowing gastric emptying, which contributes to its therapeutic effects on glycemic control and satiety. However, this same pharmacological property has been linked to a spectrum of gastrointestinal adverse reactions, including the potential development or exacerbation of gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain.

Clinical Evidence of Gastrointestinal Risks

Clinical data from placebo-controlled trials demonstrate that gastrointestinal adverse reactions occur significantly more frequently among patients receiving Ozempic compared to placebo. In the pooled analysis, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in the Ozempic groups (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include symptoms overlapping with gastroparesis.

Specific Gastrointestinal Events and Labeling Gaps

Beyond the common adverse reactions of nausea, vomiting, and diarrhea, the prescribing information also lists less frequent gastrointestinal events that are clinically relevant to gastroparesis. These include dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation (0% placebo, 2.7% Ozempic 0.5 mg, 1.1% Ozempic 1 mg), flatulence (0.8% placebo, 0.4% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these events are reported at frequencies below 5%, their presence in clinical trials underscores the potential for Ozempic to induce or worsen gastric motility disorders. The mechanistic pathway linking Ozempic to gastroparesis is rooted in its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation of these receptors inhibits gastric emptying and motility. In susceptible individuals, this pharmacodynamic effect may become pathological, leading to sustained delays in gastric emptying that meet diagnostic criteria for gastroparesis. The clinical presentation of gastroparesis includes postprandial fullness, nausea, vomiting, and abdominal discomfort—symptoms that overlap with the common gastrointestinal adverse reactions reported in Ozempic trials. Diagnosis typically involves gastric emptying scintigraphy or breath testing, and the condition can be confirmed when symptoms persist despite dose adjustment or discontinuation of the offending agent.

Risk Context and Legal Considerations

From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes a section on hypersensitivity reactions, noting that serious hypersensitivity events such as anaphylaxis and angioedema have been reported, and caution is advised in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly list gastroparesis as a warning or precaution. Instead, gastrointestinal adverse reactions are described in the context of dose escalation and tolerability, without specific guidance on monitoring for gastroparesis. This gap in labeling may affect the ability of patients and healthcare providers to recognize and address the condition early. For affected patients, attorney-related considerations involve evaluating whether the manufacturer provided adequate warnings about the risk of gastroparesis. The timeline between exposure to Ozempic and documented harm is relevant: symptoms often emerge during dose escalation or after prolonged use, and the condition may persist even after drug discontinuation. Patients who develop gastroparesis after starting Ozempic and who did not have pre-existing gastric motility disorders may have a basis for legal action if they can demonstrate that the drug caused or contributed to their condition and that warnings were insufficient. Legal claims may focus on failure to warn, design defect, or negligence in post-market surveillance. In summary, the evidence from clinical trials and prescribing information indicates that Ozempic is associated with a higher incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic plausibility of this association is supported by the drug's known effect on gastric emptying. However, the current labeling does not explicitly warn about gastroparesis, which may leave patients and clinicians unaware of the risk. For individuals who have developed gastroparesis after using Ozempic, consulting with a medical professional and an attorney experienced in pharmaceutical litigation may be appropriate to assess eligibility for legal recourse.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to or worsen gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users, including symptoms overlapping with gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the prescribing information does not explicitly list gastroparesis as a warning or precaution. Gastrointestinal adverse reactions are described generally, but specific guidance on monitoring for gastroparesis is absent (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What legal options are available for patients who developed gastroparesis after using Ozempic?

Patients may have claims for failure to warn, design defect, or negligence if they can show Ozempic caused or contributed to their gastroparesis and that warnings were inadequate. Consulting an attorney experienced in pharmaceutical litigation is recommended to assess eligibility.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.